ENIGMA is a consortium of investigators focused on determining the involvement of all unclassified variants (UV), also called variants of uncertain significance (VUS), in the BRCA1 and BRCA2 tumor suppressor genes, in predisposition to breast and ovarian cancer.
The purpose of this research-based Consortium is to facilitate classification of variants through collaborative large-scale projects by sharing data and improving classification methods.
Co-ordination of ENIGMA is funded by The National Institutes of Health Recovery Act supplement award (CA116167Z)
ENIGMA Variant Submission Guidelines
